ID

32718

Descripción

A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator; ODM derived from: https://clinicaltrials.gov/show/NCT00631007

Link

https://clinicaltrials.gov/show/NCT00631007

Palabras clave

Versiones (1)
  1. 13/11/18 13/11/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

13 de noviembre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Type 2 Diabetes Mellitus NCT00631007

Inglés

Eligibility Type 2 Diabetes Mellitus NCT00631007

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of type 2 diabetes and on either sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy for at least 3 months at stable dose
Descripción

Diabetes Mellitus, Non-Insulin-Dependent | Sulfonylureas Dose Stable | Metformin Dose Stable | Combined Modality Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C0038766
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
UMLS CUI [3,1]
C0025598
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C0205360
UMLS CUI [4]
C0009429
males and females (of non-childbearing potential or who are using dual barrier methods of contraception) between 30 and 75 years of age
Descripción

Age | Female infertility | Gender Barrier Contraception Double

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0021361
UMLS CUI [3,1]
C0079399
UMLS CUI [3,2]
C0004764
UMLS CUI [3,3]
C0205173
hba1c must be ≥7.5% and ≤10% at screening
Descripción

Hemoglobin A1c measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0474680
fasting plasma glucose must be <240 mg/dl at screening
Descripción

Plasma fasting glucose measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0583513
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of type 1 diabetes
Descripción

Diabetes Mellitus, Insulin-Dependent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011854
history of diabetic ketoacidosis
Descripción

Diabetic Ketoacidosis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011880
nyha class iii or iv cardiac status or hospitalization for congestive heart failure within 6 weeks prior to visit 1
Descripción

Cardiac Status New York Heart Association Classification | Hospitalization Due to Congestive heart failure

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1999091
UMLS CUI [1,2]
C1275491
UMLS CUI [2,1]
C0019993
UMLS CUI [2,2]
C0678226
UMLS CUI [2,3]
C0018802
treatment with any non-peroxisome proliferator-activated receptor (non-ppar) antidiabetic agent, investigational or approved, other than metformin or permitted sulfonylureas within 3 months prior to screening
Descripción

Antidiabetics Investigational | Antidiabetics Approved | Exception Peroxisome Proliferator-Activated Receptors | Exception Metformin | Exception Sulfonylureas

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C1517586
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C0205540
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0166418
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0025598
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0038766
treatment with rosiglitazone, pioglitazone, or any ppar investigational antidiabetic agent within 6 month prior to screening
Descripción

rosiglitazone | pioglitazone | Antidiabetics Investigational PPAR

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0289313
UMLS CUI [2]
C0071097
UMLS CUI [3,1]
C0935929
UMLS CUI [3,2]
C1517586
UMLS CUI [3,3]
C0166418
body mass index >45 kg/m2
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
fasting triglycerides >500 mg/dl
Descripción

Serum fasting triglyceride measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0582824
uncontrolled hypertension (sitting systolic blood pressure >160 mmhg and/or sitting diastolic blood pressure >100 mmhg
Descripción

Uncontrolled hypertension | Sitting systolic blood pressure | Sitting diastolic blood pressure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1868885
UMLS CUI [2]
C1319893
UMLS CUI [3]
C1319894
presence of diabetic complications, which in the opinion of the investigator, would complicate the subject's participation in the study (i.e., require initiation of new medication)
Descripción

Complications of Diabetes Mellitus Complicating Study Subject Participation Status | Patient need for Medication New

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0342257
UMLS CUI [1,2]
C1522701
UMLS CUI [1,3]
C2348568
UMLS CUI [2,1]
C0686904
UMLS CUI [2,2]
C0013227
UMLS CUI [2,3]
C0205314
Volver a la parte superior de la página

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00631007

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent | Sulfonylureas Dose Stable | Metformin Dose Stable | Combined Modality Therapy
Item
diagnosis of type 2 diabetes and on either sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy for at least 3 months at stable dose
boolean
C0011860 (UMLS CUI [1])
C0038766 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0025598 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205360 (UMLS CUI [3,3])
C0009429 (UMLS CUI [4])
Age | Female infertility | Gender Barrier Contraception Double
Item
males and females (of non-childbearing potential or who are using dual barrier methods of contraception) between 30 and 75 years of age
boolean
C0001779 (UMLS CUI [1])
C0021361 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0004764 (UMLS CUI [3,2])
C0205173 (UMLS CUI [3,3])
Hemoglobin A1c measurement
Item
hba1c must be ≥7.5% and ≤10% at screening
boolean
C0474680 (UMLS CUI [1])
Plasma fasting glucose measurement
Item
fasting plasma glucose must be <240 mg/dl at screening
boolean
C0583513 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Diabetes Mellitus, Insulin-Dependent
Item
history of type 1 diabetes
boolean
C0011854 (UMLS CUI [1])
Diabetic Ketoacidosis
Item
history of diabetic ketoacidosis
boolean
C0011880 (UMLS CUI [1])
Cardiac Status New York Heart Association Classification | Hospitalization Due to Congestive heart failure
Item
nyha class iii or iv cardiac status or hospitalization for congestive heart failure within 6 weeks prior to visit 1
boolean
C1999091 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
C0019993 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0018802 (UMLS CUI [2,3])
Antidiabetics Investigational | Antidiabetics Approved | Exception Peroxisome Proliferator-Activated Receptors | Exception Metformin | Exception Sulfonylureas
Item
treatment with any non-peroxisome proliferator-activated receptor (non-ppar) antidiabetic agent, investigational or approved, other than metformin or permitted sulfonylureas within 3 months prior to screening
boolean
C0935929 (UMLS CUI [1,1])
C1517586 (UMLS CUI [1,2])
C0935929 (UMLS CUI [2,1])
C0205540 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0166418 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0025598 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0038766 (UMLS CUI [5,2])
rosiglitazone | pioglitazone | Antidiabetics Investigational PPAR
Item
treatment with rosiglitazone, pioglitazone, or any ppar investigational antidiabetic agent within 6 month prior to screening
boolean
C0289313 (UMLS CUI [1])
C0071097 (UMLS CUI [2])
C0935929 (UMLS CUI [3,1])
C1517586 (UMLS CUI [3,2])
C0166418 (UMLS CUI [3,3])
Body mass index
Item
body mass index >45 kg/m2
boolean
C1305855 (UMLS CUI [1])
Serum fasting triglyceride measurement
Item
fasting triglycerides >500 mg/dl
boolean
C0582824 (UMLS CUI [1])
Uncontrolled hypertension | Sitting systolic blood pressure | Sitting diastolic blood pressure
Item
uncontrolled hypertension (sitting systolic blood pressure >160 mmhg and/or sitting diastolic blood pressure >100 mmhg
boolean
C1868885 (UMLS CUI [1])
C1319893 (UMLS CUI [2])
C1319894 (UMLS CUI [3])
Complications of Diabetes Mellitus Complicating Study Subject Participation Status | Patient need for Medication New
Item
presence of diabetic complications, which in the opinion of the investigator, would complicate the subject's participation in the study (i.e., require initiation of new medication)
boolean
C0342257 (UMLS CUI [1,1])
C1522701 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C0686904 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C0205314 (UMLS CUI [2,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial